


## Dusquetide

Cat. No.:	HY-P2076
CAS No.:	931395-42-5
Molecular Formula:	C <sub>25</sub> H <sub>47</sub> N <sub>9</sub> O <sub>5</sub>
Molecular Weight:	553.7
Sequence Shortening:	RIVPA-NH2
Target:	Bacterial
Pathway:	Anti-infection
Storage:	Sealed storage, away from moisture and light, under nitrogen
	Powder    -80°C    2 years
	-20°C    1 year



\* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)

### SOLVENT & SOLUBILITY

#### In Vitro

H<sub>2</sub>O : 50 mg/mL (90.30 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent	Mass	1 mg	5 mg	10 mg
	Concentration				
	1 mM		1.8060 mL	9.0302 mL	18.0603 mL
	5 mM		0.3612 mL	1.8060 mL	3.6121 mL
	10 mM		0.1806 mL	0.9030 mL	1.8060 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Dusquetide (SGX942) is a first-in-class innate defense regulator (IDR). Dusquetide modulates the innate immune response to both PAMPs and DAMPs by binding to p62. Dusquetide shows activity in both reducing inflammation and increasing clearance of bacterial infection<sup>[1]</sup>. DAMPs: damage-associated molecular patterns; PAMPs: pathogen-associated molecular patterns

#### In Vivo

Dusquetide (SGX942) (25 mg/kg; i.v.; days 0, 4, 7, 10, and 14) shows no increase in tumor growth or worsening of survival and a trend towards decreased tumor growth and improvement in survival with radiation<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female nude mice (MCF-7 tumor xenografts) <sup>[1]</sup>
Dosage:	25 mg/kg

---

Administration:	I.v.; days 0, 4, 7, 10, and 14
Result:	Showed no increase in tumor growth or worsening of survival and a trend towards decreased tumor growth and improvement in survival with radiation.

---

## REFERENCES

---

[1]. Kudrimoti M, et al. Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study. J Biotechnol. 2016 Dec 10;239:115-125.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA